Chester County News and Community Website
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) remains on track to seek U.S. clearance in the fourth quarter to begin clinical testing of CNTY-813, its experimental type 1 diabetes …
Century Advances Diabetes Cell Therapy Toward FDA Filing Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has exceeded its enrollment target in a pivotal hypertension trial conducted with Medtronic, moving the companies toward primary endpoint data …
Orchestra BioMed Completes Enrollment in Hypertension Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has proposed a redesigned late-stage development program for its prostate cancer drug Teverelix that could reduce planned enrollment by about 60% while …
ICYMI: Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More
WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) application to expand Imfinzi into another form of bladder cancer has received FDA Priority Review after a Phase III trial showed the drug combination …
FDA Speeds Review of AstraZeneca Bladder Cancer Regimen Read More PHILADELPHIA, PA — Medicus Pharma Ltd. is seeking U.S. Food and Drug Administration approval for a redesigned late-stage development plan that could cut enrollment in its Teverelix advanced prostate cancer …
Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More
NEWARK, DE — N-Zyme Biomedical Inc. secured $2.76 million in federal research funding to advance fosamprenavir into a Phase II trial for patients whose gastroesophageal reflux disease persists despite proton …
N-Zyme Lands $2.76 Million NIH Award for GERD Drug Trial Read More
SPRING HOUSE, PA — Johnson & Johnson’s TREMFYA met the primary and major secondary endpoints in a Phase 4 trial of adults with psoriatic arthritis and axial involvement, showing improvements …
TREMFYA Meets Key Goals in Psoriatic Arthritis Study Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has secured provisional approval and priority designation in The Bahamas for OCU400, creating a pathway to provide its investigational gene therapy to retinitis …
Ocugen Wins Bahamas Priority Path for OCU400 Gene Therapy Read More
CHESTERBROOK, PA — Persevere Therapeutics has dosed the first patient in a Phase 2a trial of misetionamide at the University of Pennsylvania’s Abramson Cancer Center, moving the experimental MYC inhibitor …
Persevere Begins Phase 2a Ovarian Cancer Trial at Penn Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (NASDAQ: APRE) will present updated interim results from its Phase 1 trial of WEE1 inhibitor APR-1051 in November, providing a new clinical readout from …
Aprea to Present Updated APR-1051 Cancer Trial Data Read More